Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing novel cellular immunotherapies for hematological cancers and solid tumors. Their clinical product candidates, including autologous GoCAR-T products and allogeneic T cell product candidates, are in various stages of clinical trials for the treatment of solid tumors expressing specific antigens and enhancing outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. The company generates revenue through collaboration and license agreements with other pharmaceutical companies and research institutions, leveraging their expertise in cellular immunotherapy to develop potential treatments for a range of cancers and blood disorders.

Products

• Cellular immunotherapies for hematological cancers and solid tumors